
### CLINICAL APPLICATIONS OF LUNG FUNCTION TEST (SPIROMETRY) IN HEALTH AND DISEASE





Prof. Sultan Ayoub Meo
MBBS, M.Phil, Ph.D (Pak), M Med Ed (Scotland)
FRCP (London), FRCP (Dublin), FRCP (Glasgow), FRCP (Edinburgh)
Professor and Consultant, Department of Physiology, College of Medicine, King Khalid University Hospital, King Saud University Riyadh, Saudi Arabia

# PULMONARY / LUNG VOLUMES AND CAPACITIES



### **SPIROMETRY**



- ☐ Spirometry is a widely used, effort depended basic lung function test
- ☐ Assess the lung performance
- ☐ Assess physiological parameters; lung volumes, capacities & flow rate
- □ Differentiate between the obstructive and restrictive lung conditions
- □ Play a critical role in the diagnosis, differentiation and management of respiratory illness.


### PHYSIOLOGICAL CONDITIONS AND SPIROMETRY



### **Physiology conditions:**

- Age, Gender, Height, Weight
- ☐ Ethnic group
- ☐ Exercise
- ☐ Posture
- Pregnancy
- Diurnal variation, seasonal, climate
- Customary activity
- Geographical location

All pulmonary volumes and capacities are about 20 to 25 % less in women than in men, and they are greater in large and athletic people than in small and asthenic people



Based on clinical features / abnormal lab tests

Symptoms: Dsyponea, cough, phlegm production, chest pain

Signs: Cyanosis, clubbing, chest deformity, diminished chest expansion, diminished breath sounds

Arterial blood gas analysis: Hypoxemia, hypercapnia

Abnormal chest X Ray:



#### Occupations settings:

**Pre employment** 

periodic lung function examination for workers exposed to toxic substances including dust and fumes in industrial sectors such as:

**Cement / Asbestoses** 

Welding / Wood / Steel

Flour / Coal mine / Oil

Meo et al., J Occup Envir Med, 2004
Meo et al., Int J Occup Med & Env Health, 2005
Meo et al., Int J Env Health Res 2006
Meo et al., Marine pollution Bulletin, 2008



Describe the course of diseases affecting PFTs

Neuromuscular diseases: Gullian Barre Syndrome, Myasthenia gravis

Pulmonary diseases: Obstructive airway diseases, Interstitial lung diseases

Adverse reactions: Drugs with known pulmonary toxicity [Pulmonary fibrosis]

#### PRE OPERATIVE INDICATIONS

To determine the suitability for and management during and after anesthesia

To assess the risk for surgical procedures known to affect lung function



Cotes 1995; ACCP Chest 2003; Regli et al., Anaesthesia, 2006



### **Monitoring indications**

To assess the therapeutic interventions:

**Bronchodilator therapy** 

Steroid treatment for asthma

**Chronic obstructive lung disease** 

**Interstitial lung disease** 

### **DIAGNOSIS OF COPD**

SYMPTOMS
cough
sputum
dyspnea


EXPOSURE TO RISK FACTORS


tobacco occupation indoor/outdoor pollution


m'


**SPIROMETRY** 























	Pred	Act1	%Act1/Pred	Act2	%Act2/Pred	%Act2/1
VC IN	4.19	3.14	74.9	3.25	77.6	103.6
IC	2.28					
ERV	1.52					
FVC	3.99	4.61	115.5	4.92	123.3	106.7
FEV 1	3.50	3.37	96.4	3.59	102.5	106.4
FEV1%F	85.83	73.20	85.3	72.94	85.0	99.6
PEF ·	8.09	8.57	105.9	7.59	93.9	88.6
FEF 25		6.87		7.59		110.5
FEF 50	4.62	2.73	59.0	2.83	61.2	103.6
FEF 75	2.02	0.90	44.5	0.91	44.9	100.9
MMEF	4.02	2.29	57.1	2.40	59.8	104.7

	Pred	Act1	%Act1/Pred	Act2	%Act2/Pred	%Act2/1
VC IN IC ERV	2.53 1.88 1.20	1.38	54.7	1.40	55.3	101.1
FVC FEV 1 FEV1%F PEF FEF 25 FEF 50 FEF 75 MMEF	3.01 2.77 92.90 5.69 5.57 4.55 1.86 3.71	2.21 1.94 88.00 3.15 3.15 2.04 1.20 1.91	73.5 70.3 94.7 55.3 56.5 44.9 64.9	2.35 1.92 81.73 3.38 2.90 1.89 0.98 1.74	78.3 69.5 88.0 59.4 52.1 41.5 53.0 46.8	106.5 98.9 92.9 107.5 92.3 92.5 81.6 91.0











Figure-6: Extracellular obstruction (e.g., tracheal involvement above the sternal notch).



Typical flattening of flow-volume loop in fixed airway obstruction




Figure-8: Fixed airway obstruction.

### **SMOKERS AND SPIROMETRY**




#### Smoker & Non Smoker:


Non Smoker: In normal healthy non smoker subject after the age of 30 the expected decline in Lung function parameter [FEV1] is 25–30 ml/annum


Smoker: The average rate of decline of lung function in smokers as measured by Forced Expiratory Volume in 1 sec [FEV1] is 60-70 ml / annum

### **SMOKERS AND SPIROMETRY**





### IMPAIRED LUNG FUNCTION IN DM





### IMPAIRED LUNG FUNCTION IN DM






Meo and Al Rubeaan, Saudi Med J; 2006

### SPIROMETRY& HbA1c

Increase in mean HbA1c is associated with decrease in lung function parameters FVC & FEV1



Davis et al., Diabetes Care 2004

Mc Keever et al., Am J Epidemiol, 2005

### SIROMETRY AND CEMENT INDUSTRY

#### **Lung Function Parameters**

- FVC
- REVI
- FEF 25-75 % and
- PEF were significantly decreased in cement mill workers compared to their matched controls



## SIROMETRY AND WELDING INDUSTRY




#### **Lung Function Parameters**

- FVC
- REV1
- PEF were significantly impaired in welding workers compared to their matched controls



### SIROMETRY AND OIL SPILL Y

Lung Function Parameters FVC, FEV<sub>1</sub>, and FEF 25-75% were impaired in subjects exposed to crude oil spill in sea water





Meo et al., Marine pollution Bulletin, 2008, Meo, et al., Int J Occup Med and Envirm Health, 2009

#### TAKE HOME MESSAGE

- ☐ The incidence of respiratory diseases has been increased, hence the importance of lung function test can not be ignored
- □ Respiratory assessment through Spirometry may be mandatory at all the levels of respiratory care / clinical settings

### TAKE HOME MESSAGE

☐ As we can not treat the patient with high blood pressure without knowing the blood pressure

☐ Similarly, we can not treat the patients with respiratory problems without knowing the lung function test [Spirometry]

